INBRX-121 and INBRX-130 are part of the company's emerging preclinical pipeline of products, which complement four of its clinical programs currently in development, Inhibrx said.

INBRX-121 is a targeted cytokine platform that is designed to overcome the limitations of Interleukin-2 (IL-2) therapy by expanding and enhancing the cytotoxic capacity of natural killer cells, the company said.

INBRX-130 is a constrained T cell redirecting and activating multispecific antibody. It targets the 5T4 antigen on solid tumors using bispecific cluster of differentiation 3 (CD3) and tumor-associated antigen targeting, the company said.

Inhibrx said that both therapies will extend its therapeutic candidates for cancer treatment.